4.5 Review

The Tempest: Difficult to Control Asthma in Adolescence

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2018.02.006

关键词

Severe asthma; Adolescent; Phenotype; Biologics; Difficult-to-treat asthma; Adherence; Psychosocial

资金

  1. American Board of Pediatrics Pediatric Pulmonary Subboard
  2. Teva
  3. GlaxoSmithKline (GSK)
  4. Merck
  5. Regeneron
  6. Novartis/Regeneron
  7. Sanofi/Regeneron
  8. Aviragen
  9. GSK/Regeneron
  10. National Institutes of Health (NIH)
  11. NIH
  12. Astra Zeneca
  13. Roche
  14. Novartis
  15. GSK

向作者/读者索取更多资源

Severe asthma is associated with significant morbidity and is a highly heterogeneous disorder. Severe asthma in adolescence has some unique elements compared with the features of severe asthma a medical provider would see in younger children or adults. A specific focus on psychological issues and adherence highlights some of the challenges in the management of asthma in adolescents. Treatment of adolescents with severe asthma now includes 3 approved biologic phenotype-directed therapies. Therapies available to adults may be beneficial to adolescents with severe asthma. Research into predictors of specific treatment response by phenotypes is ongoing. Optimal treatment strategies are not yet defined and warrant further investigation. (C) 2018 American Academy of Allergy, Asthma & Immunology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据